High specificity for PSP and CBD pathology suggested that MDS-PSP criteria for “probable 4-repeat tauopathies” are suitable for the recruitment of patients into therapeutic trials targeting 4R-tau.9 This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.